SCHEMBL1900147

SCHEMBL1900147

CSc1nc(Cl)c2c(C)cnc-2[nH]1

nearest known ligand 0.36

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 2/20 0.36
MAPT P10636 1/20 0.36
HPGD P15428 2/20 0.36
L3MBTL1 Q9Y468 2/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
NPC1 O15118 1/20 0.36
POLB P06746 1/20 0.36
MAPK1 P28482 1/20 0.36
RAB9A P51151 1/20 0.36
GFER P55789 1/20 0.36
NUDT1 P36639 1/20 0.33
HTT P42858 1/20 0.31
ALDH1A1 P00352 1/20 0.30
LMNA P02545 1/20 0.30
MAPK13 O15264 1/20 0.30
MAPK12 P53778 1/20 0.30
MAPK11 Q15759 1/20 0.30
MAPK14 Q16539 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1738564 0.77 FABP6 (0.34)
SCHEMBL1737055 0.67 AXL (0.34)
SCHEMBL3877175 0.67 HPGD (0.40) KDM4EMAPTHPGDL3MBTL1SMN1; SMN2
SCHEMBL29155626 0.65 HPGD (0.40) KDM4EMAPTHPGDL3MBTL1SMN1; SMN2
SCHEMBL7251774 0.62 L3MBTL1 (0.42) KDM4EMAPTHPGDL3MBTL1SMN1; SMN2
SCHEMBL3257090 0.62 KMT2A (0.46) KDM4EMAPTHPGDSMN1; SMN2NPC1
SCHEMBL17500019 0.62 FABP6 (0.36) KDM4EMAPTALDH1A1
SCHEMBL3577936 0.61 KDM6B (0.58) KDM4EHPGDL3MBTL1NPC1POLB
SCHEMBL22496911 0.61 JAK2 (0.34)
SCHEMBL5764763 0.60 HPGD (0.37) KDM4EMAPTHPGDSMN1; SMN2POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110124715-A1 Antiviral Oligonucleotides Having a Conserved G4 Core Sequence HANECAK RONNIE C 2011-05-26 US disclosed
US-20070015723-A1 Antiviral oligonucleotides having a conserved G4 core sequence ISIS PHARMACEUTICALS, INC. 2007-01-18 US disclosed
EP-0672193-B1 USE OF OLIGONUCLEOTIDES HAVING A CONSERVED G 4 CORE SEQUENCE FOR THE PREPARATION OF A MEDICAMENT ISIS PHARMACEUTICALS INC (US) 2002-08-14 EP disclosed
EP-1016715-A1 Oligonucleotides having a conserved G4 core sequence ISIS PHARMACEUTICALS, INC. (US) 2000-07-05 EP disclosed
EP-0691980-B1 7-DEAZAPURINE MODIFIED OLIGONUCLEOTIDES SANOFI SA (FR) 1997-06-04 EP disclosed
EP-0691980-A1 7-DEAZAPURINE MODIFIED OLIGONUCLEOTIDES STERLING WINTHROP INC (US) 1996-01-17 EP disclosed
EP-0672193-A1 OLIGONUCLEOTIDES HAVING A CONSERVED G 4? CORE SEQUENCE ISIS PHARMACEUTICALS, INC. (US) 1995-09-20 EP disclosed
WO-1994022892-A1 7-DEAZAPURINE MODIFIED OLIGONUCLEOTIDES STERLING WINTHROP INC. (US) 1994-10-13 WO disclosed
WO-1994008053-A1 OLIGONUCLEOTIDES HAVING A CONSERVED G4 CORE SEQUENCE ISIS PHARMACEUTICALS, INC. (US) 1994-04-14 WO disclosed